AU2012210142B2 - Process for preparation of a herbal extract - Google Patents
Process for preparation of a herbal extractInfo
- Publication number
- AU2012210142B2 AU2012210142B2 AU2012210142A AU2012210142A AU2012210142B2 AU 2012210142 B2 AU2012210142 B2 AU 2012210142B2 AU 2012210142 A AU2012210142 A AU 2012210142A AU 2012210142 A AU2012210142 A AU 2012210142A AU 2012210142 B2 AU2012210142 B2 AU 2012210142B2
- Authority
- AU
- Australia
- Prior art keywords
- juice
- momordica charantia
- acid
- alkali
- neutralization
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 31
- 230000008569 process Effects 0.000 title claims description 30
- 238000002360 preparation method Methods 0.000 title description 19
- 239000012676 herbal extract Substances 0.000 title description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 90
- 244000302512 Momordica charantia Species 0.000 claims description 51
- 235000009811 Momordica charantia Nutrition 0.000 claims description 47
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
- 239000000843 powder Substances 0.000 claims description 29
- 239000000284 extract Substances 0.000 claims description 25
- 239000002775 capsule Substances 0.000 claims description 21
- 239000003513 alkali Substances 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 150000007524 organic acids Chemical class 0.000 claims description 13
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 238000006386 neutralization reaction Methods 0.000 claims description 12
- 230000002378 acidificating effect Effects 0.000 claims description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006187 pill Substances 0.000 claims description 5
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- 235000005979 Citrus limon Nutrition 0.000 claims description 3
- 244000131522 Citrus pyriformis Species 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 235000011054 acetic acid Nutrition 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- 229940112822 chewing gum Drugs 0.000 claims description 3
- 235000015218 chewing gum Nutrition 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000007937 lozenge Substances 0.000 claims description 3
- 235000010603 pastilles Nutrition 0.000 claims description 3
- -1 sachet Substances 0.000 claims description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- 238000001291 vacuum drying Methods 0.000 claims description 3
- 238000009777 vacuum freeze-drying Methods 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 2
- 235000021022 fresh fruits Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 description 18
- 239000000470 constituent Substances 0.000 description 13
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000000605 extraction Methods 0.000 description 9
- 238000003756 stirring Methods 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 239000002585 base Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229940069328 povidone Drugs 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910002012 Aerosil® Inorganic materials 0.000 description 3
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 3
- 229940038472 dicalcium phosphate Drugs 0.000 description 3
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 3
- 239000000428 dust Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004159 blood analysis Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- WRZYGPIFICWRCG-OOFFSTKBSA-M sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trih Chemical compound [Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O WRZYGPIFICWRCG-OOFFSTKBSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010051602 Laziness Diseases 0.000 description 1
- 235000009815 Momordica Nutrition 0.000 description 1
- 241000218984 Momordica Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 229930185803 charantin Natural products 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002542 deteriorative effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 239000008368 mint flavor Substances 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- WTGQALLALWYDJH-WYHSTMEOSA-N scopolamine hydrobromide Chemical compound Br.C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-WYHSTMEOSA-N 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Description
PROCESS FOR PREPARATION OF A HERBAL EXTRACT
FIELD
The present disclosure relates to a process for preparation of a herbal extract powder.
More particularly, the present disclosure relates to a process for preparation of a herbal extract powder from Momordica charantia.
BACKGROUND
and subtropical vine of the family Cucurbitaceae, widely grown in Asia, Africa and the Caribbean for its edible fruit, which is among the most bitter of all fruits. There are many varieties that differ substantially in the shape and bitterness of the fruit.
Processes for extraction of the active constituents from various parts Momordica charantia and the formulations these constituents have been disclosed in Indian Patent 81887, GB 1435664, ΓΝ156263, US5098710, JP31 12999, CN1 180545, US6852695, US6831 162 IN191582, CN1253734 CN1303698, ΓΝ188858, IN826/DEL/2000, IN768/MUM/2001 , CN1418890, JP2005126370,CN 1562340, CN1858223, JP2006314273, CN1709900, CN1872134, JP2008120701, TW200927139, CN101366806, CN101461514, CN101485429, CN101597389 and CN101637491.
The hitherto reported processes for extraction of the active constituents from various parts Momordica charantia suffer from several limitations which include : use of organic solvents for extraction, use of heat during processing, use of
enzymes during the extraction process, use of sophisticated equipments for the extraction process.
Also, the formulations comprising the Momordica constituents suffer from numerous short-comings which include lower shelf life, reduction in the potency and high cost on account of high processing.
There is therefore felt a need for a process for extraction of the active constituents from Momordica charantia which is simple, cost effective, which does not employ any harmful Organic solvents and which enhances the potency of the constituents. A need is also felt for_a_formulation-Comprising-activ^ constituents of-Momordica' charantia which is simple, effective and potent as compared to the existing product.
OBJECT
Some of the objects of the present disclosure are as follows:
It is an object of the present disclosure to provide a process for preparation of an extract of Momordica charantia which has a longer shelf life.
It is another object of the present disclosure to provide a process for preparation of an extract of Momordica charantia which does not employ any enzymes.
It is still another object of the present disclosure to provide a process for preparation of an extract of Momordica charantia which does not employ organic solvents.
It is yet another object of the present disclosure to provide a process for preparation of an extract of Momordica charantia which increases the potency of the extract.
It is yet another object of the present disclosure to provide a process for preparation of an extract of Momordica charantia wherein the end product is non- hygroscopic.
SUMMARY
In accordance with the present disclosure there is provided a process for preparing an extract of Momordica charantia comprising Jhe-following steps:
a) preparing crude juice from crushed and chopped unripe Momordica charantia fresh fruit to which water is added intermittently;
b) filtering the crude juice to obtain filtered juice;
c) modifying the pH of the juice between 2.5 to 4 pH by adding an
organic acid;
d) allowing the pH modified juice to stabilize by allowing the pH added filtered juice to stand for 5 to 25 minutes;
e) neutralizing the stabilized juice with the help of alkali;
f) allowing the neutralized juice to stand for a period of 20 to 30 minutes; g) rechecking the pH level of the juice for neutralization; and
h) drying the neutralized juice to obtain dried extract of Momordica charantia.
Typically, the organic acid is at least one selected from the group consisting of citric acid, acetic acid, lactic acid, tartaric acid and oxalic acid.
Typically, the organic acid is citric acid.
Typically, the organic acid is lemon juice.
Typically, the acidic pH is adjusted to a value of 3.8.
Typically, the alkali used for neutralization is at least one alkali selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide and sodium bicarbonate.
Typically, the normality of the alkali used for neutralization is in the range of 0.1 N to 4 N.
In accordance with the present disclosure, during the step of neutralization the alkali is added dropwise in the stabilized acidic juice.
In accordance with the present disclosure, the dried extract is obtained by treating the neutralized juice in at least one manner selected from the group consisting of spray drying, vacuum drying and freeze drying to obtain a dried extract of Momordica charantia.
There is also provided a formulation containing the dried extract of Momordica charantia prepared in accordance with the present disclosure in a dosage form selected from the group consisting of powder, granule, capsule, tablet, sachet, suspension, liquid, pastille, chewing gum, lozenges and pill.
DETAILED DESCRIPTION
In one aspect, the present disclosure provides a process for preparation of a herbal extract powder from Momordica charantia. The first and foremost consideration before the commencement of any herbal extraction process is the selection of the
particular plant part for the purposes of extraction. Accordingly, the first step in accordance of the process with the present disclosure is selection of the raw material.
In accordance with the process of the present disclosure, fruits are used as the raw material for the extraction process.
Typically, green colored unripe fruits are used as the raw material.
Typically, the fruits that are used as the raw material are fresh.
A crude juice is prepared by crushing and chopping the fruits with intermittent addition of water. The crude juice is then subjected to filtration to obtain a green coloured juice.
A pH modifying agent is added to render the green coloured juice acidic by adjusting the pH to a predetermined value.
Typically, a mild organic acid is used as the pH modifying agent.
Typically, the organic acid is at least one selected from the group consisting of citric acid, acetic acid, lactic acid, tartaric acid, oxalic acid and or the like, or the combinations thereof.
In accordance with one embodiment, citric acid is used as the pH modifying agent. The organic acid used as a pH modifying agent may be obtained from a natural source. Alternatively, the organic acid may be purely synthetic. In one embodiment, lemon juice is used as the pH modifying agent. In another embodiment, citric acid is used as the pH modifying agent.
Typically, the pre-determined pH value is selected from the values selected from the group consisting of 2.5, 3, 3.5 and 4.
In accordance with one embodiment of the disclosure, the predetermined value of pH is in the range of about 3.5 to about 4.0.
In accordance with still another embodiment of the present disclosure, the predetermined value of pH is 3.8.
It is believed that the addition of the organic acids in the clear juice converts the
fractions, which help in reduction of blood glucose levels in patients.
The acidic juice extract with a predetermined pH is allowed to stabilize for a period in the range of about 5 min to 25 min, preferably, in the range of about 15 to 20 minutes.
The stabilized acidic juice is neutralized by addition of an alkali to obtain a neutralized juice extract with a pH in the range of about 6.5 to 7.
In accordance with a preferred embodiment of the present disclosure, the pH of the neutralized juice is about 7.
Typically, in the method step of neutralization of the acidic juice using an alkali, after the addition of the alkali to the acidic juice, the neutralized juice is kept aside for a period of about 20 to 30 minutes and the pH is re-checked. If necessary, additional alkali is added to re-adjust the pH in a range of about 6.5 to about 7, preferably about 7.
Typically, the alkali used for the neutralization of the acid juice include but are not limited to sodium hydroxide, potassium hydroxide, calcium hydroxide, sodium bicarbonate or the like, or the combinations thereof.
Typically, the normality of the alkali used for neutralization of the acid juice is in the range of 0.1 N to about 4N.
Typically, the alkali is added in a drop-wise manner in the stabilized acidic juice for a time period ranging between 5 to 10 minutes.
Neutralization of ^acidiG-juiee-ensures-the-prevention-of'iurther-degradatiOn^of peptides in amino acids. Therefore, the fraction prepared from fresh green unripe fruits of Momordica charantia (bitter gourd) in accordance with the process of the present disclosure is found to be more potent as compared to the juice obtained from the whole fruit.
The neutralized juice extract thus obtained-is dried by at least one manner selected from the group consisting of spray drying, vacuum drying and freeze drying to obtain a dried extract of Momordica charantia.
The Polypeptide-p, charantin and bitter constituents of Momordica charantia fruits show anti-diabetic activity.
In accordance with another aspect of the present disclosure, there is provided a herbal composition that comprises the dried extract of Momordica charantia prepared by the process in accordance with the present disclosure.
Typically, the herbal composition is formulated in a dosage form selected from the group consisting of powder, granule, capsule, tablet, sachet, suspension, liquid, pastille, chewing gum, lozenges and pill.
The present disclosure will now be described with the help of following non- limiting examples.
Examples
Preparation of Momordica charantia powder
Example 1 - 5 Kg of fresh unripe green fruits along with seeds of Momordica charantia Linn were subjected to cleaning to remove the dust and other superfluous particles from the fruits. The cleaned fruits were chopped and grinded to obtain homologous slurry with the addition of approximately 500 ml of water. The slurry was then filtered to separate the juice by using the nutch filter. The juice was then acidified with 15% of citric acid under continuous stirring to adjust the pH to 4^0. The stirring of juice was continued for-30 minutes and again pH was noted. After stabilization of pH, the pH of acidified juice was then neutralized with help of 15% sodium hydroxide solution to obtain pH to 7.0. The neutralized juice was then subjected to continuous stirring for 30 minutes and pH was once again noted to confirm the pH - 7.0. The juice with neutral pH was then concentrated under constant vacuum at 700 mm of Hg at temperature 55°C to obtained juice with 18 brix (total solid content). The concentrated juice was dried using vacuum dryer adjusted at 60°C and reduced pressure, which gave 176 gm of the greenish brown coloured free flowing juice powder with characteristic taste and odour.
Analysis of the juice powder showed following constituents in Table 1.
Table 1.
Constituents
Proteins 22.85
Bitters 3.32
Example 2 - 5 Kg of fresh unripe green fruits along with seeds of Momordica charantia Linn were subjected to cleaning to remove the dust and other superfluous particles from the fruits. The cleaned fruits were chopped and grinded to obtain homologous slurry with the addition of approximately 500 ml of water. The slurry was then filtered to separate the juice by using the high speed centrifuge. The juice was then acidified with 15% of citric acid under continuous stirring to adjust the pH to 4.0. The stirring of juice was continued for 30 minutes and again pH was noted. After stabilization of pH, the pH of acidified juice was then neutralized with help of 15% sodium hydroxide solution to obtain pH to 7.0. The neutralized juice was then subjected to continuous stirring for 30 minutes and pH was once again noted to confirm the pH - 7.0. The juice with neutral pH was then concentrated under constant vacuum at 700 mm of Hg at temperature 55°C to obtained juice with 16 brix (total solid content). The concentrated juice was dried using spray dryer at 155°C inlet temperature, 70°C to 80°C outlet temperature, which gave 159 gm of greenish brown coloured free flowing juice powder with characteristic taste and odour. Analysis of the juice powder showed following constituents in Table 2.
Table 2.
Constituents
Proteins 22.15
Bitters 2.76
Example 3 - 5 Kg of fresh unripe green fruits along with seeds of Momordica charantia Linn were subjected to cleaning to remove the dust and other superfluous particles from the fruits. The cleanedjruits were chopped_and_grinded to obtain homologous slurry with the addition of approximately 500 ml of water. The slurry was then filtered to separate the juice by using the high speed centrifuge. The juice was then acidified with 15% of oxalic acid under continuous stirring to adjust the pH to 4.0. The stirring of juice was continued for 30 minutes and again pH was noted. After stabilization of pH, the pH of acidified juice was then neutralized with help of 15% Calcium hydroxide solution to obtain pH to 7.0. The neutralized juice was then subjected to continuous stirring for 30 minutes and pH was once again noted to confirm the pH - 7.0. The juice with neutral pH was then concentrated under constant vacuum at 700 mm of Hg at temperature 55°C to obtained juice with 18 brix (total solid content). The concentrated juice was dried using freeze dryer adjusted at -46°C and reduced pressure, which gave 165 gm of green coloured free flowing juice powder with characteristic taste and odour. Analysis of the juice powder showed following constituents in Table 3.
Table 3.
Preparation of capsules of Momordica charantia 400 mg.
Example 4 - The juice powder of Momordica charantia, microcrystalline cellulose, aen½ij,^ic^cium phosphatejwere-sifted through 40-US-mesh sereen blended"and granulated using an aqueous solution of Povidone (PVPK-30). The granules were then dried at temperature of 60 + 5° C, sifted through 30 US mesh screen, lubricated and filled into hard gelatin capsule shells of suitable
The capsules had composition as given below in Table 4.
Table 4.
Ingredients Quantity per mg in capsule
Juice powderof Momordica charantia of example 1 400
Microcrystalline cellulose 100
Aerosil 3
Dicalcium phosphate 40
Povidone (PVPK-30) 5.5
Magnesium stearate 3
Talc 3
Sodium starch glycolate 15
Preparation of granules of Momordica charantia
Example 5 - The juice powder of Momordica charantia, sodium carboxymethyl cellulose, sodium saccharin, citric acid and sodium glycyrrhizinate were sifted through 40 US mesh screen, blended and granulated. The granules were then dried at temperature of 60 + 5° C, sifted through 30 US mesh screen filled either in bulk or in unit dose per pack.
The granules had composition as given below in Table 5.
Table 5.
Ingredients Quantity in mg
Juice powderof Momordica charantia of example 1 400
Sodium glycyrrhizinate 10
Sodium citrate 20
Mint flavour (0.1%) 1
Sodium carboxy methyl cellulose 2
Sodium saccharin 1
Preparation of tablets of Momordica charantia fraction 600 mg.
Example 6 - The juice powder of Momordica charantia of example 1 , microcrystalline cellulose, aerosil, dicalcium phosphate were sifted through 40 US mesh screen, blended and granulated using an aqueous solution of Povidone (PVPK-30). The granules were then dried at temperature of 60 + 5° C, sifted through 30 US mesh screen and lubricated using talc, magnesium stearate and sodium starch glycolate. The lubricated granules were then compressed using suitable die and punches and coated.
The tablets had composition as given below in Table 6.
Table 6.
Ingredients Quantity per mg in tablet
Juice powderof Momordica charantia of example 1 600
Microcrystalline cellulose 100
Aerosil 20
Dicalcium phosphate 50
Povidone (PVPK-30) 10
Magnesium stearate 5
Talc 5
Sodium starch glycolate 25
Hydroxy propyl methyl cellulose 8
Titanium dioxide 5
Propylene glycol 3
Anecdotal studies:
1) A subject with uncontrolled type II diabetes was administered three capsules of Momordica charantia extracts in accordance with the present disclosure per day containing 400 mg extract per capsule; as obtained from Example 4.
It was found that blood glucose level of the subject was reduced to 159 mg/dL from its base level - 249 mg/dL during one month of treatment at a dose of one capsule (400mg) administered three times a day.
) A test was made of the hypoglycemic effect of the same juice powder of M. charantia as employed in Example 4 upon a female patient of 56 years of age and a body weight of 61 kg presenting with non insulin-dependent diabetes. The test subject exhibited a daily blood glucose level of 234 mg/dL, with administration of 500 mg of metformin; BID.
The subject continued administration of the same number of pills of metformin per day and commenced ingestion of 3 hard gelatin capsules containing 400 mg of Juice powder of M. charantia per capsule as obtained from example 4 for a period of 90 days. The practiced dosage regimen was 1 capsule before breakfast and 2 capsules before dinner.
The blood analysis of patient showed dramatic effect where the blood glucose level of the subject reduced to 170 mg/dL from its base level - 234 mg/dL during a three month of treatment. During the treatment, the patient was on a^ very jnoderate diet and she was physically moderately active. ) A test was made of the hypoglycemic effect of the same juice powder of M. charantia as employed in Example 4 upon a non insulin-dependent uncontrolled diabetic male of 61 years of age and a body weight of 67 kg. The subject had long history of diabetes and was on oral medication from more than 5 years. The test subject exhibited a daily blood glucose level of 261 mg/dL, with administration of 500 mg of metformin; three tablets per day.
The subject continued administration of the same number of pills of metformin per day and commenced ingestion of 3 hard gelatin capsules containing 400 mg of Juice powder of M. charantia per capsule as obtained from example 4 for a period of 90 days. The practiced dosage regimen was 1 capsule before breakfast and 2 capsules before dinner.
The blood analysis of the patient showed dramatic effect where the blood glucose level of the subject reduced to 159 mg/dL from its base level - 261 mg/dL during a three month of treatment. ) -A-male subject-of-62- years with uneontrolled-maturity onset "diabetes was administered 3 capsules of commercially available Momordica charantia extract per day containing 400 mg of commercial powder per capsule.
It was found that after a period of one month blood glucose level of the subject reduced from a base level of 249 mg/dL to 199 mg/dL consistently.
Thereafter under the same conditions, the subject was administered one capsule as per example 4, three times a day. After one month treatment, the blood glucose level of the subject reduced to 159 mg/dL. ) A female subject of 70 years with uncontrolled maturity onset diabetes was administered 3 capsules of commercially available Momordica charantia extract per day containing 400 mg of commercial powder per capsule.
It was found that after a period of one month, the blood glucose level of the subject reduced from a base level of 265 mg/dL to 215 mg/dL consistently.
Thereafter under the same conditions, the subject was administered one capsule as per example 4, three times a day. After one month treatment, the blood glucose level of the subject reduced to 145 mg/dL.
Safety profile
No toxic effects or side effects were ascertained in the testings mentioned above. The physical status of examined persons showed no sign of any harmful reaction to treatment. The dosage regimen as well as treatment were patient friendly and well tolerated by diabetics.
Other Benefits:
Besides controlling the blood/urine sugar level the nutraceutical product(s) provide additional benefits in diabetes related human health problems like reduction in fatigue, weakness, drowsiness, numbing effect, frequent urination, unusual thirst and hunger, weight loss, swellings on legs/ankles, burning sensation on feet, palms, relief in skin itching, skin dryness, black patches on skin, hypertension, increase in sleep comfort, energetic feeling, improvement in laziness, blurred vision, frequent skin infections and slow healing of wounds and sores.
A 20-35% reduction in blood glucose doses was also observed after 12 weeks in noninsulin-dependent diabetes mellitus (NIDDM) adult diabetics and can be also used as adjuvant therapy along with oral treatments.
The present disclosure thus provides the specific composition of Momordica charantia juice powder, the process for the preparation of juice powder and the medicinal benefits of the same.
Technical advancement: The process for preparation of Momordica charantia juice powder and the formulation synthesized in accordance with the present disclosure has the following non-limited advancements:
- The present disclosure provides a process for the preparation of a nutraceutical food supplement for diabetics without deteriorating the nutritional and pharmaceutical properties of the natural composition like enrichment of proteins and bitters that are responsible for hypoglycemic activity.
- The process for the preparation of Momordica charantia juice powder in -accordance with the present-disclosure is simple and ost effectiveT
- The process for the preparation of Momordica charantia juice powder in accordance with the present disclosure is safe as it does not involve use of any harmful solvents.
- The Momordica charantia juice powder prepared in accordance with the present disclosure is comparatively more effective against diabetes.
- The Momordica charantia juice powder prepared in accordance with the present disclosure is a natural food which is non toxic, easy to digest with optimum nutrition, health protective and promotive properties.
Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.
The use of the expression "at least" or "at least one" suggests the use of one or more elements or ingredients or quantities, as the use may be in the embodiment of the invention to achieve one or more of the desired objects or results.
Any discussion of documents, acts, materials, devices, articles or the like that has been included in this specification is solely for the purpose of providing a context for the invention. It is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the invention as it existed anywhere before the priority date of this application.
The numerical values given for various physical parameters, dimensions and quantities are only approximate values and it is envisaged that the values higher than the numerical value assigned to the physical parameters, dimensions and quantities fall within the scope of the invention and the claims unless there is a statement in the specification to the contrary.
The foregoing description of the specific embodiments will so fully reveal the general nature of the embodiments herein that others can, by applying current knowledge, readily modify and/or adapt for various applications such specific embodiments without departing from the generic concept, and, therefore, such adaptations and modifications should and are intended to be comprehended within the meaning and range of equivalents of the disclosed embodiments. It is to be understood that the phraseology or terminology employed herein is for the purpose of description and not of limitation. Therefore, while the embodiments herein have been described in terms of preferred embodiments, those skilled in the art will recognize that the embodiments herein can be practiced with modification within the spirit and scope of the embodiments as described herein.
Claims (10)
1. A process for preparing an extract of Momordica charantia comprising the following steps:
a) preparing crude juice from crushed and chopped unripe Momordica charantia fresh fruit to which water is added intermittently;
b) filtering the crude juice to obtain filtered juice;
c) modifying the pH of the juice between 2.5 to 4 pH by adding an
organic acid;
d) allowing the pH modified juice to stabilize by allowing the pH added filtered juiee-to stand -for-5-to-25 -minutes;
e) neutralizing the stabilized juice with the help of alkali;
f) allowing the neutralized juice to stand for a period of 20 to 30 minutes; g) rechecking the pH level of the juice for neutralization; and
h) drying the neutralized juice to obtain dried extract of Momordica charantia.
2. A process as claimed in claim 1 , wherein the organic acid is at least one selected from the group consisting of citric acid, acetic acid, lactic acid, tartaric acid and oxalic acid.
3. A process as claimed in claim 1 , wherein the organic acid is citric acid.
4. A process claimed in claim 1, wherein the organic acid is lemon juice.
5. The process as claimed in any one of the preceding claims in which the acidic pH is adjusted to a value of 3.8.
6. The process as claimed in any one of the preceding claims in which the alkali used for neutralization is at least one alkali selected from the group consisting of sodium hydroxide, potassium hydroxide, calcium hydroxide and sodium bicarbonate.
7. The process as claimed in any one of the preceding claims, wherein the normality of the alkali used for neutralization is in the range of 0.1 N to 4 N.
8. The process as claimed in any one of the preceding claims, wherein during the step of neutralization the alkali is added dropwise in the stabilized acidic juice.
9. The process as claimed in any one of the preceding claims, wherein the dried extract is obtained by treating the neutralized juice in at least one manner selected from the group consisting of spray drying, vacuum drying and freeze drying to obtain a dried extract of Momordica charantia,
10. A formulation containing the dried extract of Momordica charantia prepared in accordance with any one of the claims in a dosage form selected from the group consisting of powder, granule, capsule, tablet, sachet, suspension, liquid, pastille, chewing gum, lozenges and pill.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN246MU2011 | 2011-01-28 | ||
| IN246/MUM/2011 | 2011-01-28 | ||
| PCT/IN2012/000059 WO2012101657A1 (en) | 2011-01-28 | 2012-01-27 | Process for preparation of a herbal extract |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2012210142A1 AU2012210142A1 (en) | 2013-08-15 |
| AU2012210142A8 AU2012210142A8 (en) | 2013-09-12 |
| AU2012210142B2 true AU2012210142B2 (en) | 2016-05-12 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010209051A (en) | Fat absorption inhibitor | |
| EP2667884B1 (en) | Process for preparation of an extract of momordica charantia | |
| KR101396458B1 (en) | A food or drink composition comprising fermented eastern prickly pear | |
| WO2014017243A1 (en) | Sleep quality improving agent | |
| JP2016193882A (en) | Anti-aging agent | |
| CN104398561A (en) | Medicinal and edible variety composition for preventing and treating alcoholic liver diseases, and its preparation method | |
| CN108635551A (en) | Soboring-up liver-protecting Chinese medicine composition, preparation and preparation method and application | |
| AU2012210142B2 (en) | Process for preparation of a herbal extract | |
| KR100979882B1 (en) | Diabetic prevention and treatment composition containing gold and silver extract and red ginseng extract | |
| DE202008015430U1 (en) | Composition for the treatment of indigestion | |
| KR101528557B1 (en) | A pharmaceutical composition comprising fermented Eastern prickly pear | |
| JP6273440B2 (en) | GLP-1 production promoter, DPPIV inhibitor and glucose absorption inhibitor | |
| NZ613666B (en) | Process for preparation of a herbal extract | |
| KR101423316B1 (en) | Composition for prevention or treatment of osteoarthritis including extracts of Phyllanthus tenellus | |
| NZ613666A (en) | Process for preparation of a herbal extract | |
| JP2001046019A (en) | Nutritional composition derived from citrus | |
| JPWO2020100917A1 (en) | Prophylactic and / or therapeutic agents for neurodegenerative diseases | |
| US20240207327A1 (en) | Composition including propolis and sorbus commixta as active ingredients for alleviating and treating inflammatory diseases and allergic diseases | |
| WO2019218537A1 (en) | Chitosan composition and preparation method therefor | |
| JP5265177B2 (en) | Composition for improving bowel movements containing acacia bark | |
| KR20050101143A (en) | Methods and composition for the prevention and improvement of degenerative arthritis including glucosamin | |
| WO2008072725A1 (en) | Composition containing agaricus blazei murill | |
| JP2006193501A (en) | Adiponectin regulator, food and drink containing the same, food additive and medicine | |
| KR20170005873A (en) | Oral composition for improving systemic symptoms including sensitivity to cold | |
| JP2023158841A (en) | Oral composition |